Cargando…

Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s disease

Alzheimer’s disease (AD) is the most common form of dementia in the elderly, and affects millions of people worldwide. As the number of AD cases continues to increase in both developed and developing countries, finding therapies that effectively halt or reverse disease progression constitutes a majo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferreira, Sergio T., Lourenco, Mychael V., Oliveira, Mauricio M., De Felice, Fernanda G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4443025/ https://www.ncbi.nlm.nih.gov/pubmed/26074767 http://dx.doi.org/10.3389/fncel.2015.00191

Ejemplares similares

Brain metabolic stress and neuroinflammation at the basis of cognitive impairment in Alzheimer’s disease
por: De Felice, Fernanda G., et al.
Publicado: (2015)

Cerebrospinal fluid irisin correlates with amyloid‐β, BDNF, and cognition in Alzheimer's disease
por: Lourenco, Mychael V., et al.
Publicado: (2020)

Hyperactivity Induced by Soluble Amyloid-β Oligomers in the Early Stages of Alzheimer's Disease
por: Hector, Audrey, et al.
Publicado: (2021)

Interleukin-1β mediates alterations in mitochondrial fusion/fission proteins and memory impairment induced by amyloid-β oligomers
por: Batista, Andre F., et al.
Publicado: (2021)

How do Soluble Oligomers of Amyloid β-protein Impair Hippocampal Synaptic Plasticity?
por: Li, Shaomin, et al.
Publicado: (2010)

Amyloid β-protein oligomers and Alzheimer’s disease
por: Hayden, Eric Y, et al.
Publicado: (2013)

β-Amyloid oligomers in aging and Alzheimer’s disease
por: Zahs, Kathleen R., et al.
Publicado: (2013)

Neonatal infection leads to increased susceptibility to Aβ oligomer-induced brain inflammation, synapse loss and cognitive impairment in mice
por: Frost, Paula S., et al.
Publicado: (2019)

Amyloid-β oligomers link depressive-like behavior and cognitive deficits in mice
por: Ledo, J H, et al.
Publicado: (2012)

Formation of soluble amyloid oligomers and amyloid fibrils by the multifunctional protein vitronectin
por: Shin, Thuzar M, et al.
Publicado: (2008)

Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects
por: Frozza, Rudimar L., et al.
Publicado: (2018)

Disruption of Amyloid Plaques Integrity Affects the Soluble Oligomers Content from Alzheimer Disease Brains
por: Jimenez, Sebastian, et al.
Publicado: (2014)

Correction: Amyloid-β oligomers link depressive-like behavior and cognitive deficits in mice
por: Ledo, J. H., et al.
Publicado: (2020)

Doxycycline for Alzheimer’s Disease: Fighting β-Amyloid Oligomers and Neuroinflammation
por: Balducci, Claudia, et al.
Publicado: (2019)

Altered synaptic structure in the hippocampus in a mouse model of Alzheimer’s disease with soluble amyloid-β oligomers and no plaque pathology
por: Price, Katherine A, et al.
Publicado: (2014)

Alzheimer Amyloid-β Oligomer Bound to Post-Synaptic Prion Protein Activates Fyn to Impair Neurons
por: Um, Ji Won, et al.
Publicado: (2012)

Soluble Aβ Oligomers Formed Channels Leading to Calcium Dysregulation
por: Li, Shaomin
Publicado: (2023)

Soluble Amyloid Oligomers Increase Bilayer Conductance by Altering Dielectric Structure
por: Sokolov, Yuri, et al.
Publicado: (2006)

Probing the Occurrence of Soluble Oligomers through Amyloid Aggregation Scaling Laws
por: Silva, Alexandra, et al.
Publicado: (2018)

Amyloid-β oligomers set fire to inflammasomes and induce Alzheimer's pathology
por: Salminen, Antero, et al.
Publicado: (2008)

Cajaninstilbene Acid Ameliorates Cognitive Impairment Induced by Intrahippocampal Injection of Amyloid-β(1–42) Oligomers
por: Wang, Li-Sha, et al.
Publicado: (2019)

Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease
por: Mroczko, Barbara, et al.
Publicado: (2018)

The Toxicity of Amyloid β Oligomers
por: Zhao, Li Na, et al.
Publicado: (2012)

Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression
por: Tolar, Martin, et al.
Publicado: (2021)

Synaptic proteasome is inhibited in Alzheimer’s disease models and associates with memory impairment in mice
por: Ribeiro, Felipe C., et al.
Publicado: (2023)

Synaptic Disruption by Soluble Oligomers in Patients with Alzheimer’s and Parkinson’s Disease
por: Gutierrez, Berenice A., et al.
Publicado: (2022)

Editorial: Beta-Amyloid oligomer specific treatments for Alzheimer's disease
por: Hillen, Heinz
Publicado: (2023)

Postsynaptic Receptors for Amyloid-β Oligomers as Mediators of Neuronal Damage in Alzheimer’s Disease
por: Dinamarca, Margarita C., et al.
Publicado: (2012)

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
por: Hölttä, Mikko, et al.
Publicado: (2013)

Irisin stimulates protective signaling pathways in rat hippocampal neurons
por: Lourenco, Mychael V., et al.
Publicado: (2022)

Breaking the Code of Amyloid-β Oligomers
por: Lesné, Sylvain E.
Publicado: (2013)

The Toxicity and Polymorphism of β-Amyloid Oligomers
por: Huang, Ya-ru, et al.
Publicado: (2020)

Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers
por: Laurén, Juha, et al.
Publicado: (2009)

Characterization of a Novel Mouse Model of Alzheimer’s Disease—Amyloid Pathology and Unique β-Amyloid Oligomer Profile
por: Liu, Peng, et al.
Publicado: (2015)

Early diagnosis and treatment of Alzheimer’s disease by targeting toxic soluble Aβ oligomers
por: Habashi, Maram, et al.
Publicado: (2022)

A Luminex Assay Detects Amyloid β Oligomers in Alzheimer’s Disease Cerebrospinal Fluid
por: Herskovits, Adrianna Z., et al.
Publicado: (2013)

Amyloid-β oligomers unveil a novel primate model of sporadic Alzheimer's disease
por: Jebelli, Joseph D., et al.
Publicado: (2015)

Stabilization of a Membrane-Associated Amyloid-β Oligomer for Its Validation in Alzheimer's Disease
por: Serra-Batiste, Montserrat, et al.
Publicado: (2018)

Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid
por: Yang, Ting, et al.
Publicado: (2019)

The Therapeutic and Diagnostic Potential of Amyloid β Oligomers Selective Antibodies to Treat Alzheimer’s Disease
por: Viola, Kirsten L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mq9uh9lgdtgc7jebj77l8lh199